Travoprost monotherapy effective for POAG

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

In a 5-year study reported in the Journal of Glaucoma, 36 previously untreated POAG patients received topical travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories), once in the evening in both eyes.

All patients received a pre-treatment 24-hour IOP evaluation, followed by a series of 5 follow-up 24-hour evaluations at 12-month intervals throughout the trial.

In the 34 patients who completed the study, the travoprost monotherapy reduced the mean 24-hour IOP from 23.4 (±1.7) mmHg at baseline to the following:

  • 16.8 (±2.4) mmHg at the 1-year assessment, a 28.4% decrease in IOP from baseline.
  • 16.8 (±2.5) mmHg at the 2-year assessment (-28.1% from baseline)
  • 16.8 (±2.4) mmHg at the 3-year assessment (-28.5% from baseline)

  • 16.7 (±2.5) mmHg at the 4-year assessment (-28.6% from baseline)
  • 16.9 (±2.4) mmHg at the 5-year assessment (-27.8% from baseline)

To read an abstract of the study, click here.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
POAG study hope to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma
Gonio-intervention robot-assisted glaucoma surgical procedure offers high precision
Related Content
© 2023 MJH Life Sciences

All rights reserved.